Triterpene cyclase and application thereof

Through gene mining and yeast cell expression technology, the discovery of AmAS, a 6-6-5 cyclic triterpene cyclase, solved the shortcomings in the biosynthesis pathway of syrup triterpene compounds, and achieved support for efficient synthesis and new drug development.

CN119020339AActive Publication Date: 2024-11-26INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310614802.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-11-26
Estimated Expiration
2043-05-26

AI Technical Summary

Technical Problem

The natural resources of stinky 6-6-5 cyclic triterpenes are scarce, chemical synthesis is difficult, and the research on cyclases and genes responsible for biosynthesis is extremely limited, especially in the lack of applied research on enzymatic synthesis activity.

Method used

Through gene mining technology, it was discovered and functionally identified the 6-6-5-cyclic triterpene cyclase AmAS, and used heterologous expression of yeast cells to identify its catalytic function, and generated mutants through amino acid replacement to improve catalytic activity and substrate specificity. , and provide encoding nucleic acid molecules and recombinant expression vectors to achieve biosynthesis.

Benefits of technology

The efficient synthesis of stinky triterpene compounds was achieved, avoiding the problems of poor stereoselectivity and high cost of chemical synthesis, providing new chemical entity molecules for the research and development of new drugs, and providing new methods for biosynthetic pathways.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004253523390000031
    Figure BDA0004253523390000031
  • Figure BDA0004253523390000041
    Figure BDA0004253523390000041
  • Figure BDA0004253523390000061
    Figure BDA0004253523390000061
Patent Text Reader

Abstract

The invention discloses a triterpenoid cyclase, a nucleic acid molecule for coding the triterpenoid cyclase, an expression vector containing the nucleic acid molecule, an engineered microorganism containing the corresponding vector, and application of the triterpenoid cyclase in production of ailanthus type 6-6-5-ring triterpenes. Site-specific mutagenesis is carried out on the basis of the triterpenoid cyclase, and the obtained mutated triterpenoid cyclase can generate triterpenoid analogues with various structures and biological activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to a novel triterpene cyclase derived from Astragalus mongolica of the Leguminosae family and an application thereof. Background Art

[0002] Triterpenes are a class of compounds with a wide range of biological and pharmacological activities. The most widely distributed triterpenes in plants are tetracyclic triterpenes and pentacyclic triterpenes, while Ailanthus-type 6-6-5-cyclic triterpenes are relatively rare. So far, more than 50 Ailanthus and its Ailanthus glycoside compounds have been reported in plants (Domingo, V.; Arteaga, JF; Quílez Del Moral, JF; Barrero, AF Unusually Cyclized Triterpenes: Occurrence, Biosynthesis and Chemical Synthesis. Nat. Prod. Rep. 2009, 26, 115–134. Stonik, VA; Kolesnikova, SAMalabaricane and Isomalabaricane Triterpenoids, Including Their Glycoconjugated Forms. Mar. Drugs 2021, 19, 327. (c) Xu, R.; Fazio, GC; Matsuda, SP On the Origins of Triterpenoid Skeletal Diversity. Phytochemistry 2004, 65, 261–291.).

[0003] Due to the complex structure and synthesis process of triterpenes, the content in plants is low and the extraction and separation are difficult, which limits their large-scale application. The use of biotechnology to analyze the biosynthetic pathway of triterpenes can effectively increase the content of target metabolites, or use synthetic biology methods to reconstruct its biosynthetic pathway in vitro to produce triterpenes. The main enzyme involved in the formation of triterpenes is oxidosqualene cyclases, which can catalyze the precursor 2,3-epoxysqualene to form different types of triterpene skeletons. So far, more than 170 cyclases have been functionally identified in plants, most of which are responsible for the synthesis of tetracyclic triterpenes, cycloartenol synthases, lupeol synthases and β-amyrin synthases (Wang, J.; Guo, Y.; Yin, X.; Wang, X.; Qi, X.; Xue, Z. Diverse Triterpene Skeletons Are Derived from The Expansion and Divergent Evolution of 2,3-Oxidosqualene Cyclases in Plants. Crit. Rev. Biochem. Mol. 2022, 57, 113–132. Thimmappa, R.; Geisler, K.; Louveau, T.; O'Maille, P.; Osbourn, A. Triterpene Biosynthesis in Plants. Annu. Rev. Plant Biol.2014.65,225–257.Tao,H.;Lauterbach,L.;Bian,G.;Chen,R.;Hou,A.;Mori,T.;Cheng,S.;Hu,B.;Lu,L.;Mu,X. ;Li,M.;Adachi,N.;Kawasaki,M.;Moriya,T.;Senda,T.;Wang,X.;Deng,Z.;Abe,I.;Dickschat,JS;Liu,T.Discovery ofNon-Squalene Triterpenes. Nature, 2022, 606, 414–419.).However, there are few reports on the cyclases responsible for the synthesis of tricyclic triterpenoids. Currently, there are only two cyclases, AtPEN1 and AtPEN4, from the plant Arabidopsis thaliana (Xiang, T.; Shibuya, M.; Katsube, Y.; Tsutsumi, T.; Otsuka, M.; Zhang, H.; Masuda, K.; Ebizuka, YA New Triterpene Synthase from Arabidopsisthaliana Produces a Tricyclic Triterpene with Two Hydroxyl Groups. Org. Lett. 2006, 8, 2835–2838. Fazio, GC; Xu, R.; Matsuda, SPT Genome Mining to Identify New Plant Triterpenoids. J. Am. Chem. Soc. 2004, 126, 5678–5679.).

[0004] In summary, the current research on Ailanthus-type 6-6-5-cyclic triterpenes and their analogs has the following limitations and shortcomings:

[0005] 1. There are few natural resources of Ailanthus-type 6-6-5-ring triterpenoid compounds, and chemical synthesis is difficult;

[0006] 2. There is very limited research on the cyclase and its genes responsible for the biosynthesis of Ailanthus-type 6-6-5-ring triterpene skeletons, especially on the application of enzymatic synthesis of active Ailanthus-type 6-6-5-ring triterpene compounds. Summary of the invention

[0007] In order to overcome the defects of the prior art, the present invention uses gene mining technology to mine and functionally identify the key cyclases in the biosynthetic pathway of Ailanthus 6-6-5-ring triterpenes. These results lay the foundation for the analysis of the complete biosynthetic pathway of Ailanthus 6-6-5-ring triterpenes and the creation of artificial pathways to a certain extent.

[0008] In a first aspect, the present invention provides a novel Ailanthus altissima (Malabaricanes) 6-6-5-ring triterpene cyclase AmAS, whose amino acid sequence is shown in SEQ ID NO.1, or an amino acid sequence having at least 90% identity with the amino acid sequence shown in SEQ ID NO:1 and having the activity of catalyzing the production of triterpene compounds. The Ailanthus altissima (Malabaricanes) 6-6-5-ring triterpene cyclase (AmAS) provided by the present invention can be identified by gene mining and heterologous expression in yeast cells for its catalytic function.

[0009] In a second aspect, the present invention provides a nucleic acid molecule encoding the triterpene cyclase AmAS. Preferably, the nucleic acid sequence of the nucleic acid molecule is as shown in SEQ ID NO.2, or has more than 90% homology with the sequence shown in SEQ ID No.2. The nucleic acid molecule can be cloned from Astragalus membranaceus, Astragalus mongolica and other Astragalus plants.

[0010] In a third aspect, the present invention provides a recombinant expression vector comprising the nucleic acid molecule.

[0011] In a fourth aspect, the present invention provides an engineered microorganism comprising the nucleic acid molecule or the recombinant expression vector.

[0012] In a fifth aspect, the present invention provides the use of the triterpene cyclase, the nucleic acid molecule, the recombinant expression vector or the engineered microorganism in the production of Ailanthus type 6-6-5-ring triterpenes.

[0013] As a preferred embodiment of the present invention, the Ailanthus-type 6-6-5-cyclic triterpene has a structure as shown in Formula 1 or Formula 2:

[0014]

[0015] In a sixth aspect, the present invention provides a mutant of the triterpene cyclase based on the triterpene cyclase.

[0016] As a specific embodiment, the mutant triterpene cyclase provided by the present invention has an amino acid sequence as shown in SEQ ID NO.1, and the 256th amino acid Q in the sequence is mutated to L or W (named AmAS-L / W). In a specific example, the catalytic activity of the AmAS-L / W mutant is analyzed by amino acid replacement amplification and heterologous expression in yeast cells.

[0017] As a specific embodiment, the mutant triterpene cyclase provided by the present invention has an amino acid sequence as shown in SEQ ID NO.1, and the 258th amino acid Y in the sequence is mutated to A or H (named as AmAS-A / H). In a specific example, the catalytic activity of the AmAS-A / H mutant is analyzed by amino acid replacement amplification and heterologous expression in yeast cells.

[0018] As a specific embodiment, the mutant triterpene cyclase provided by the present invention has an amino acid sequence as shown in SEQ ID NO.1, and the 256th amino acid Q in the sequence is mutated to L, and the 258th amino acid Y is mutated to H (named AmAS-LH). In a specific example, the catalytic activity of the AmAS-LH mutant is analyzed by amino acid replacement amplification and heterologous expression in yeast cells.

[0019] As a specific embodiment, the mutant triterpene cyclase provided by the present invention has an amino acid sequence as shown in SEQ ID NO.1, and the amino acid IIH at positions 725-727 of the sequence is mutated to VFM (named AmAS-VFM). In a specific example, the catalytic activity of the AmAS-VFM mutant is analyzed by amino acid replacement amplification and heterologous expression in yeast cells.

[0020] As a specific embodiment, the mutant triterpene cyclase provided by the present invention has an amino acid sequence as shown in SEQ ID NO.1, and the amino acid IIH at positions 725-727 of the sequence is mutated to VFN (named AmAS-VFN). In a specific example, the AmAS-VFN mutant can change the substrate specificity through amino acid replacement amplification and yeast cell heterologous expression to obtain different types of triterpenes.

[0021] In a seventh aspect, the present invention provides a nucleic acid molecule encoding the mutated triterpene cyclase described in the sixth aspect.

[0022] In an eighth aspect, the present invention provides a recombinant expression vector comprising the nucleic acid molecule described in the seventh aspect.

[0023] In a ninth aspect, the present invention provides an engineered microorganism comprising the nucleic acid molecule of the seventh aspect or the recombinant expression vector of the eighth aspect.

[0024] In a tenth aspect, the present invention provides the use of the mutated triterpene cyclase, nucleic acid molecule, recombinant expression vector or engineered microorganism in the production of Ailanthus type 6-6-5-ring triterpenes.

[0025] As a preferred embodiment of the present invention, the AmAS-VFN mutant produces Ailanthus-type 6-6-5-cyclic triterpenes as shown in Formula 3, 4, 5, 6 or 7:

[0026]

[0027] Additional Notes

[0028] Unless otherwise specified, the scientific and technological terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. The present invention may also be implemented using any methods and materials similar to or equivalent to those described herein, and specific implementation methods and preferred methods and materials are described herein without limiting the present invention in any way.

[0029] Beneficial technical effects

[0030] The Ailanthus altissima type 6-6-5 ring triterpene cyclase of the present invention can efficiently synthesize the biosynthetic precursors of Ailanthus altissima type triterpene compounds, avoiding the defects of chemical synthesis methods such as poor stereo and regional selectivity, protection and deprotection of functional groups, long routes, high costs, and environmental pollution, and does not require extraction from plants, providing a new method for obtaining Ailanthus altissima type triterpene compounds. In addition, site-directed mutagenesis of the enzyme can obtain triterpene compounds with diverse structures, providing new chemical entity molecules for new drug research and development. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 , GC-MS spectra of the fermentation products of cyclase AmOSC2 in yeast; (a) GC chromatogram of the fermentation products of AmOSC2 in yeast; (b) EI-MS spectra of compounds 1 and 2.

[0032] Figure 2 , GC-MS spectra of the fermentation products of the site-directed mutants of cyclase AmAS in yeast; (a) GC chromatogram of the fermentation products of cyclase AmAS and its mutants in yeast, including (i) IIH725-727VFN, (ii) IIH725-727VFM, (iii) Q256W / Y258H, (iv) Q258H, (v) Q258A, (vi) Q256M, (vii) Q256L, (viii) wildtype; (b) EI-MS spectra of compound 3 and Lupeol standard.

[0033] Figure 3 , MS spectra of the fermentation products of AmAS site-directed mutant IIH725-727VFN in yeast; among them, (a) EI-MS spectrum of compound 4, (b) EI-MS spectrum of compound 5, (c) EI-MS spectrum of compound 6, and (d) EI-MS spectrum of compound 7. DETAILED DESCRIPTION

[0034] The following specific examples are provided to further illustrate various aspects of the present invention. These examples are non-limiting and should not be construed as limiting any aspect of the present invention. The scope of protection of the present invention is limited only by the claims. Without departing from the scope of the claims, those skilled in the art may make various modifications and improvements to various aspects of the present invention, and these modifications and improvements also belong to the scope of protection of the present invention. For example, replacing the promoter and expression vector used in the examples with other promoters and expression vectors commonly used in the art is something that can be understood and implemented by those of ordinary skill in the art.

[0035] In addition, it should be noted that, unless otherwise specified, the various materials and reagents used in the following examples are commonly used materials and reagents in the art and can be obtained through conventional commercial channels; the methods used are conventional methods known to those skilled in the art.

[0036] Example 1: Cloning of AmAS gene

[0037] 1. Transcriptome sequencing and mining of Ailanthus-type 6-6-5-ring triterpene cyclases

[0038] Mongolian Astragalus was collected from the Medicinal Botanical Garden of the Temple of Heaven Park in Beijing. Fresh roots were taken during the experiment, quickly frozen with liquid nitrogen, and stored at –80°C for later use. The transcriptome sequencing of fresh roots of Mongolian Astragalus and the data analysis of raw data were commissioned to BGI. According to the results of the raw data analysis, the AtPEN1 sequence reported in Arabidopsis thaliana was used as a probe to screen the candidate genes of triterpene cyclases in Astragalus that may be involved in the biosynthesis of Ailanthus-type triterpene compounds through local BLAST. Bioedit was used to analyze the ORFs of the candidate genes, and online servers such as ExPASy and TMHMM were used to predict the physicochemical properties and transmembrane structures of the candidate genes.

[0039] 2. Total RNA Extraction and First-strand cDNA Synthesis

[0040] Fresh roots of Astragalus membranaceus were used as the material for total RNA extraction. Total RNA was extracted according to the instructions of EZNATM Plant RNAKit. After extraction, the integrity of total RNA was detected by 0.8% non-deformed agarose gel electrophoresis, and the OD260 nm / OD280 nm ratio and RNA concentration were determined by UV spectrophotometer. TransscriptⅡFirst-Strand cDNA Synthesis Super Mix was used to synthesize the first strand of cDNA.

[0041] 3. Target gene amplification

[0042] (1) PCR reaction system: Based on the full-length information of the candidate genes obtained by screening, specific primers are designed and the full-length amplification of the candidate genes is performed using cDNA as a template. The reaction system is shown in Table 1.

[0043] Table 1: PCR reaction system

[0044] Reagents Volume (μL) Final concentration 10×KODBuffer 5 1× 2mM dNTPs 5 200μM <![CDATA[25mMMgSO4]]> 3 1.5mM 10 μM Forward Primer 1 0.2μM 10μM Reverse Primer 1 0.2μM cDNA 1 >200ng KOD-Plus-Neo 1 1U <![CDATA[ddH2O]]> Top up to 50

[0045] For candidate genes that do not contain complete ORFs, RACE primers (5′-RACE or / and 3′-RACE primers) were designed based on the transcriptome sequence information, and the 5′-end or / and 3′-end of the candidate gene was obtained by RACE-PCR, and the full length of the candidate gene was further spliced, and the complete ORFs were predicted. According to the upstream and downstream sequences of ORFs, specific primers were designed to amplify ORFs and sequence verification was performed. The RACE-PCR reaction system is shown in Table 2.

[0046] Table 2: PCR reaction system

[0047]

[0048]

[0049] (2) PCR reaction conditions (Touchdown): pre-denaturation at 94°C for 2 min; denaturation at 98°C for 10 s, annealing at 68°C for 30 s, annealing at a gradient of 0.5°C per cycle, extension at 68°C for 30 s / kb, for 36 cycles; denaturation at 98°C for 10 s, annealing at 50°C for 30 s, extension at 68°C for 30 s / kb, for 15 cycles. After the last cycle, keep the mixture at 68°C for 5 min to allow full amplification and store at 4°C.

[0050] (3) PCR product detection, recovery and sequencing verification The PCR product was detected by agarose gel electrophoresis, and the product with the correct band size was excised and recovered for purification. According to the instructions, the purified PCR product was connected to the cloning vector pEASY-Blunt and transformed into DH-5α Escherichia coli competent cells. Positive clones were selected by blue-white screening and colony PCR for sequencing verification, and finally the sequencing results were compared with the target gene sequence.

[0051] Example 2: Expression and functional identification of AmAS gene

[0052] 1. Construction of recombinant expression vector

[0053] The candidate gene AmAS in Example 1 was recombined using a homologous recombination kit II One Step Cloning Kit is used to construct recombinant expression vectors. This kit uses the principle of homologous recombination. When designing the PCR primers for the key enzyme gene, a segment (15 bp in size) and a sequence identical to the two ends of the linearized vector (such as pESC-His vector) are introduced at the 5′ end of a pair of primers, and then the PCR product is cloned in a directional manner, so that the recombination is not restricted by the restriction site, the PCR product does not need to be digested by enzymes, and no ligase is used. The experimental process is as follows.

[0054] (1) Preparation of linearized empty vector: The pESC-His / Leu / Ura vector was digested with BamH I restriction enzyme according to the instruction manual, and the linear vector product was recovered by gel excision.

[0055] (2) Preparation of PCR product (target gene): Add a 15 bp base sequence homologous to the linearized vector to the 5′ end of each PCR primer (Table 3). Use the synthesized primers with vector homologous sequences to amplify the target gene containing the vector homologous arms, and then cut the gel to recover the target gene fragment.

[0056] Table 3: Specific primer sequences

[0057] Primer name Nucleic acid sequence (5' to 3') AmOSC2-pESC-His-F aggagaaaaaaccccATGTGGAAGTTGAAGATAGCAGAAG AmOSC2-pESC-His-R agtgagtcgtattacTTAAAGCCAAGTTGCGGCATTT

[0058] (3) Homologous recombination and transformation of linear vector and target gene fragment: Add each component according to the homologous recombination reaction system shown in Table 4, mix gently, incubate in a PCR instrument at 37°C for 30 min and immediately place on ice. Transform Trans1-T1 competent cells with the ligation product, incubate at 42°C for 45 s, incubate at 42°C for 2 min, add 500 μL LB culture medium and incubate at 37°C, 200 rpm for 1 h, spread an appropriate amount of bacterial solution on solid LB medium containing ampicillin, and after overnight culture, pick a single colony for colony PCR verification, and select positive clones for sequencing to verify the correctness of the insertion of the target gene.

[0059] Table 4: Homologous recombination reaction

[0060] Reagents Volume (μL) Linearized vector X Target gene fragment Y 5xCEIIBuffer 2 ExnaseII 1 <![CDATA[ddH2O]]> Make up to 10 μL

[0061] Note: X / Y is calculated according to the formula (the optimal usage of linearized vector and insert fragment is 0.03 and 0.06 pmol).

[0062] 2. Construction of heterologous expression system for candidate triterpene cyclases

[0063] The positive transformants verified by sequencing were cultured overnight in LB medium and the recombinant plasmids (pESC-His-AmOSCs, pESC-Ura-tHMG1 and pESC-Leu-ERG7) with the target gene inserted were extracted using a kit. - ) and used the yeast transformation kit Frozen-EZYeast TransformationⅡTM to transform S.cerevisiae INVSc1, cultured on nutrient-deficient solid medium (SD-HLU), extracted plasmids and PCR reaction to verify whether the heterologous expression system was successfully constructed.- Yeast S. cerevisiae INVSc1 was co-transformed as a negative control IN-0 (Table 5).

[0064] Table 5: Plasmid composition of yeast engineering bacteria

[0065] Strain name Plasmid composition Control <![CDATA[pESC-His / pESC-Ura-tHMG1 / pESC-Leu-ERG7 - ]]> AMS <![CDATA[pESC-His-AmAS / pESC-Ura-tHMG1 / pESC-Leu-ERG7 - ]]>

[0066] (1) Preparation of Saccharomyces cerevisiae INVSc1 competent cells

[0067] a. Inoculate the activated S.cerevisiae INVSc1 cells in 10 mL YPDA and culture at 30°C with shaking at 220 rpm until the OD600 is 0.8-1.0;

[0068] b. Centrifuge at 500×g for 4 min at 4°C to collect cells and discard the supernatant carefully;

[0069] c. Add 10 mL of Frozen-EZYeast Solution 1, centrifuge at 500 × g, 4 ° C for 4 min, and discard the supernatant;

[0070] d. Add 1 mL of Frozen-EZYeast Solution 2 and resuspend the cells;

[0071] e. Aliquot the cells in d into 50 μL / tube, wrap with paper towels and place in –70℃ for gradual freezing and storage.

[0072] (2) Yeast transformation of recombinant plasmid

[0073] a. Take 5 μL of the sequencing-verified recombinant plasmids, i.e., pESC-His-AmCASs, pESC-Ura-tHMG1, and pESCLeu-ERG7, and add them to 50 μL of yeast competent cells, and then add 500 μL of Frozen-EZYeast Solution 3 and mix thoroughly.

[0074] b. Incubate in a 30°C water bath for 45 min, vortexing 2-3 times every 15 min;

[0075] c. Spread 100 μL of the above transformation mixture on SD-HLU plates and culture inverted at 30°C for 2-4 days.

[0076] (3) Yeast plasmid extraction and PCR verification

[0077] a. Inoculate an appropriate amount of positive clones into 10 mL SD-HLU liquid medium and culture at 30°C, 220 rpm for 24 h;

[0078] b. Take 4 mL of yeast culture, centrifuge at 8,000 rpm for 2 min to collect the bacteria, and pour out or dry the culture medium;

[0079] c. Remove yeast cell wall: add 600μL enzymatic buffer, 1.2μL β-mercaptoethanol and 50μL Snailase to every 20mg bacterial pellet, and incubate at 37℃ for 3h. Centrifuge at 5,000rpm for 10min, discard the supernatant, and collect the precipitate; add 250μL Solution I to the bacterial pellet, and pipette or shake until the bacteria are completely suspended;

[0080] d. Add 250 μL Solution II, immediately gently invert the tube 5-10 times to mix, and let stand at room temperature for 2-4 minutes;

[0081] e. Add 350 μL Solution III, gently invert the tube 5-10 times to mix thoroughly, and centrifuge at 12,000 rpm for 10 min;

[0082] f. Carefully transfer all the supernatant into the adsorption column, place at room temperature for 2 minutes, centrifuge at 8,000 rpm for 2 minutes, and discard the liquid in the collection tube;

[0083] g. Add 500 μL Buffer DW1 to the adsorption column, 10,000 rpm for 1 min, and pour out the liquid in the collection tube;

[0084] h. Add 500 μL Wash Solution to the adsorption column, 10,000 rpm for 1 min, and pour out the liquid in the tube

[0085] i. Place the adsorption column and empty collection tube into a centrifuge and centrifuge at 12,000 rpm for 2 min;

[0086] j. Place the adsorption column in a clean 1.5 mL centrifuge tube, add 50 μL of Eliution Buffer to the center of the adsorption membrane, let stand at room temperature for 2 minutes, centrifuge at 10,000 rpm for 1 minute, collect the yeast plasmid in the centrifuge tube, and the obtained plasmid DNA solution can be stored at -20°C;

[0087] k. Using the extracted yeast plasmid DNA as a template, the universal primers of the vector and the gene-specific primers were used as primer pairs to screen the target gene, and PCR reaction was performed according to the system in Table 6 to verify the success of the construction of the heterologous expression system.

[0088] Table 6: Yeast plasmid PCR reaction system

[0089] Reagents Volume (μL) 2×EsTaqMix 5 Specific upstream primer 0.4 There is a universal primer downstream 0.4 Yeast plasmid DNA 4.2

[0090] PCR reaction conditions: 94℃ pre-denaturation for 2min, 94℃ denaturation for 30s, 55℃ annealing for 30s, 72℃ extension for 30s / kb, 30 cycles. After the last cycle, keep at 72℃ for 5min to fully amplify the reaction mixture and store at 4℃.

[0091] 3. Functional verification of candidate triterpene cyclases in yeast

[0092] After 2 days of activation culture of the positive transformants verified by PCR on SD-HLU solid medium, an appropriate amount was selected and inoculated into 10 mL of SD-HLU medium and cultured at 30°C and 220 rpm for 24 h. The cells were collected by centrifugation at 1000 × g for 6 min, washed twice with sterile water, and resuspended in SG-HLU medium to an initial OD of 600 Between 0.6 and 0.8, continue induction culture at 30°C and 220rpm for 5 days. Collect the cells by centrifugation at 1,000×g, wash the cells with deionized water and weigh them, add 40mL 20% potassium hydroxide and 60mL 50% ethanol per gram of wet weight of the cells, evenly suspend them, and then ultrasonically treat them for 90 minutes to lyse the yeast cell wall. The lysate is extracted with n-hexane 3-4 times, the organic layer is evaporated to dryness under reduced pressure, the residue is re-dissolved with n-hexane, filtered, and analyzed by GC-MS. The results are as follows: Figure 1 As shown. GC-MS analysis showed that compared with the control group, AmAS R = 27.5min, a major product 1 was produced. R = 23.3min, a small by-product peak 2 was produced, with molecular weights of 444 and 426 respectively.

[0093] Example 3: Preparation and structural identification of AmAS catalytic products

[0094] 1. Preparation of target products catalyzed by AmAS

[0095] The yeast engineered bacteria constructed in Example 2 was scaled up for fermentation and cultured to 10 L. After 5 days of induction culture according to the operating method of Example 2, the bacteria were collected by centrifugation, subjected to alkaline lysis, n-hexane extraction and reduced pressure concentration. The obtained residue was re-dissolved in ethyl acetate and separated by normal semi-preparative high performance liquid chromatography (n-hexane:ethyl acetate=10:1, 4 mL / min). Combined with GC-MS detection, the fraction where the target compound was located was obtained, and further purified by reverse phase HPLC-UV (ACN, 1 mL / min, 203 nm) to obtain the main product arabidiol (1), and purified by reverse phase HPLC-UV (95% ACN, 1 mL / min, 203 nm) to obtain a secondary product (2).

[0096] 2. Determination of the target product structure

[0097] All prepared compounds were dissolved in deuterated chloroform for NMR analysis ( 1 H-NMR, 13 C-NMR) was used to analyze the structure of the compound (Table 7). Combined with the data reported in the literature, compound 1 is a Malabaricane triterpene compound arabido. The NMR data of compound 2 are similar to those of compound 1. The main difference is that there is one less methyl signal at C-27 and two more olefin proton signals (δ H =4.90,4.76), and finally the structure of compound 2 was determined to be (3S,13S)-malabarica-14(27),17,21-trien-3-ol by 2D-NMR.

[0098]

[0099] Table 7 Compounds 1 and 2 1 H and 13 C NMR data (δin ppm, Jin Hz)

[0100]

[0101]

[0102] 1 H(400MHz)and 13 C(100MHz)NMR data in chloroform-do overlapped signals.

[0103] Example 4: Key amino acids for AmAS function

[0104] 1. Multiple sequence alignment and site-directed mutagenesis

[0105] In order to identify the key amino acids for the catalytic activity of the cyclase AmAS, ClustalW in MEGA7 software was used to perform multiple sequence alignment of AmAS with functionally confirmed cyclases in plants; based on the comparison results, amino acid residues Q256, Y258 and IIH725-727 in AmAS were preferentially selected for further study. Specific primers were designed and seven sets of site-directed mutagenesis experiments were performed (Table 8).

[0106] Table 8 Site-directed mutagenesis specific primer design

[0107]

[0108]

[0109] Using the overlapping PCR method, the plasmid containing the wild-type AmAS was used as a template, and 7 sets of specific primers were used for PCR amplification to obtain the target fragment. After the PCR was completed, the endonuclease DpnI was used to digest and remove the wild-type template to obtain the purified fragment. The fragments were connected using a seamless connection kit (Nanjing Novozyme Co., Ltd.), and then transformed into Escherichia coli DH-5α, and the positive clones were obtained by sequencing verification (Table 9). The site-directed mutagenesis-positive recombinant plasmid was transferred into S.cerevisiae INVSc1 competent cells, and the wild strain AmAS was used as a negative control. The successfully transformed mutant engineered bacteria were subjected to 50ml induction expression (three parallel experiments). After 7 days of fermentation, the yeast cell extract was lysed with alkali solution and extracted with n-hexane for GC-MS analysis. The results are as follows Figure 2 As shown. Compared with the control group, the main product arabidiol was produced in trace amounts in Q256L / W, Y258A / H, Q256W-Y258H and IIH725-727VFM mutants, and no corresponding new product peaks appeared; in the IIH725-727VFN mutant, although the production of arabidiol decreased by 45%, it was still the main product, and 5 new product peaks appeared. Compared with the standard, it can be seen that compound 3 is a known compound Lupeol.

[0110] Table 9 Site-directed mutagenesis yeast engineering bacteria plasmid composition

[0111]

[0112]

[0113] 2. Preparation and structure determination of AmAS-VFN mutant products

[0114] The mutant strain AmAS IIH-725-727VFN A 20 L scale-up fermentation was performed. Compounds 4-7 were prepared by various separation instruments and analyzed by EI-MS (results as shown in Figure 3 shown), NMR ( 1 H-NMR, 13 C-NMR, DEPT135, 1 H- 1The structures of compounds 4-7 were determined by H COSY, HSQC, HMBC and NOESY), optical rotation analysis and existing literature reports, namely (3S,13R)-malabarica-14(27), 17,21-trien-3β-ol(4), (20E)-dammara-20(22), 24-dien-3β-ol(5), (3S,13S)-malabarica-17,21-dien-3β,14-diol(6) and (20R)-dammarenediol I(7) (Tables 10 and 11).

[0115] Table 10 1 H and 13 C NMR data of compounds 4and 6 (δin ppm, Jin Hz).

[0116]

[0117]

[0118] Table 11 1 H and 13 C NMR data of compounds 5and 7 (δin ppm, Jin Hz).

[0119]

[0120]

Claims

1. A triterpene cyclase AmAS, characterized in that The amino acid sequence is as shown in SEQ ID NO.1, or an amino acid sequence which is at least 90% identical to the amino acid sequence as shown in SEQ ID NO:1 and has the activity of catalyzing the production of triterpene compounds.

2. A nucleic acid molecule encoding the triterpene cyclase AmAS according to claim 1; Preferably, the nucleic acid sequence of the nucleic acid molecule is as shown in SEQ ID No. 2, or has more than 90% homology with the sequence shown in SEQ ID No.

2.

3. A recombinant expression vector comprising the nucleic acid molecule according to claim 2.

4. An engineered microorganism comprising the nucleic acid molecule of claim 2 or the recombinant expression vector of claim 3.

5. Use of the triterpene cyclase according to claim 1, the nucleic acid molecule according to claim 2, the recombinant expression vector according to claim 3 or the engineered microorganism according to claim 4 in producing Ailanthus type 6-6-5-ring triterpenes; Preferably, the Ailanthus-type 6-6-5-cyclic triterpene has a structure as shown in Formula 1 or Formula 2:

6. A mutant triterpene cyclase, characterized in that It has an amino acid sequence as shown in SEQ ID NO.1, and the 256th amino acid Q in the sequence is mutated to L or W; Alternatively, it has an amino acid sequence as shown in SEQ ID NO.1, and the 258th amino acid Y in the sequence is mutated to A or H; Alternatively, it has an amino acid sequence as shown in SEQ ID NO.1, and the 256th amino acid Q in the sequence is mutated to L, and the 258th amino acid Y is mutated to H; Alternatively, it has an amino acid sequence as shown in SEQ ID NO.1, and the amino acids IIH at positions 725-727 of the sequence are mutated to VFM; Alternatively, it has an amino acid sequence as shown in SEQ ID NO.1, and the amino acids IIH at positions 725-727 of the sequence are mutated to VFN.

7. A nucleic acid molecule encoding the mutated triterpene cyclase according to claim 6.

8. A recombinant expression vector comprising the nucleic acid molecule of claim 7.

9. An engineered microorganism comprising the nucleic acid molecule of claim 7 or the recombinant expression vector of claim 8.

10. Use of the mutant triterpene cyclase according to claim 6, the nucleic acid molecule according to claim 7, the recombinant expression vector according to claim 8 or the engineered microorganism according to claim 9 in producing Ailanthus type 6-6-5-ring triterpenes; Preferably, the Ailanthus-type 6-6-5-cyclic triterpene has a structure as shown in Formula 3, 4, 5, 6 or 7:

Citation Information

Patent Citations

  • Triterpenoid cyclase for producing prototerpane triterpenes as well as coding sequence, expression vector and application of triterpenoid cyclase

    CN114854727A

  • Tripterygium wilfordii triterpene synthase twosc1, coding gene therefor, and application thereof

    WO2020029564A1